Table 3.

Adherence to SAGER Guidelines.

Scheme	No. of Interventional Vaccine Trials Complying with the Recommendation	No. of Observational Vaccine Trials Complying with the Recommendation	Overall %
1. Introduction: Sex and gender differences in the infection, manifestation, or outcomes of COVID-19 should be acknowledged in the introduction.	0/42	2/33	3%
(2a) Methodology: Papers should report how sex and gender were taken into account in the design of the study.	0/42	2/33	3%
(2b) Methodology: Papers should justify reasons for the exclusion, or differing numbers, of males or females.	1/42	1/33	3%
(3a) Results: “Sex- and gender-based analyses should be reported regardless of positive or negative outcome” [10]. Articles should note if there is a difference between sexes or genders, or if there is no difference, in their results.	7/41	10/29	24%
(3b) Results: Articles should report all their data disaggregated by sex.	7/41	10/29	24%
(4) Discussion: What the results of the study mean for women and men should be analysed in the discussion section.	2/42	8/33	13%
(5) Generalizability: If a sex and gender analysis is not done, this should be justified or addressed in relation to the generalizability of the results.	2/42	3/33	7%